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associations of clinical parameters reflecting disease processes and AKI development.
Methods: We performed an observational cohort study of 223 consecutive COVID-19 patients treated at 3
sites of a tertiary care referral center to describe the evolvement of severe AKI (Kidney Disease: Improving
Global Outcomes stage 3) and identify conditions promoting its development. Descriptive statistics and
explanatory multivariable Cox regression modeling with clinical parameters as time-varying covariates
were used to identify risk factors of severe AKI.
Results: Severe AKI developed in 70 of 223 patients (31%) with COVID-19, of which 95.7% required kidney
replacement therapy. Patients with severe AKI were older, predominantly male, had more comorbidities, and
displayed excess mortality. Severe AKI occurred exclusively in intensive care unit patients, and 97.3% of the pa-
tients developing severe AKI had respiratory failure. Mechanical ventilation, vasopressor therapy, and inflam-
matory markers (serum procalcitonin levels and leucocyte count) were independent time-varying risk factors of
severe AKI. Increasing inflammatory markers displayed a close temporal association with the development of
severe AKI. Sensitivity analysis on risk factors of AKI stage 2 and 3 combined confirmed these findings.
Conclusion: Severe AKI in COVID-19 was tightly coupled with critical illness and systemic inflammation
and was not observed in milder disease courses. These findings suggest that traditional systemic AKI
mechanisms rather than kidney-specific processes contribute to severe AKI in COVID-19.
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OVID-19, the disease caused by the pandemic
SARS-CoV-2 virus, remains a major global health
threat with continuously rising case numbers.1 While
the disease is primarily affecting the respiratory system,
there is increasing evidence for the importance of kid-
ney involvement. Early data from China suggested that
acute kidney injury (AKI) occurred only in a small905
CLINICAL RESEARCH J-HB Hardenberg et al.: Severe AKI in COVID-19minority of patients, with rates of AKI ranging from
0.5% to 5.1% and that kidney replacement therapy
(KRT) was required only in 0.8%.2,3 In contrast, reports
from New York of patients treated during the surge in
March and April 2020 showed that AKI may be very
frequent.4,5 In the Mount Sinai health care system,
43% of hospitalized COVID-19 patients developed
AKI. AKI requiring KRT developed in 8.6% of all pa-
tients and in 34% of intensive care unit (ICU) patients.6
Administrative data from Germany show that KRT was
required in 22.8% of hospitalized COVID-19 patients.7
These numbers suggest the kidney to be the second
most affected organ in patients with COVID-19.8–10
The precise etiology of AKI in COVID-19 has not
been fully elucidated.11,12 Mild kidney abnormalities,
such as hematuria or proteinuria, have been reported
early in the course of COVID-19, suggesting direct
renal effects of SARS-CoV-2.13 In severely ill patients
with COVID-19, direct renal tropism of SARS-CoV-2
has been reported and may impact kidney function
and contribute to the severity of AKI.14–16
Nevertheless, other studies showed no evidence of viral
tropism and indicated that acute tubular necrosis is the
predominant injury pattern.17–22 In addition, large retro-
spective cohort studies indicated that the severe stages of
AKI occurred almost exclusively in critically ill patients
with respiratory failure treated in ICUs.4–6,23–25 These latter
observations would be consistent with a critical illness–
associated pathophysiology that frequently underlies
non–COVID-associated forms of AKI.26–29
We reasoned that the detailed clinical courses of
patients with COVID-19 may provide additional impor-
tant clues to the pathophysiology of COVID-associated
AKI. In particular, the association of AKI with COVID-
19 disease severity and its temporal association with
the disease course might be informative. Previous
studies of AKI in COVID-19 had focused on the rela-
tionship of clinical baseline characteristics at hospital
admission with AKI development.4,5,22 However,
because COVID-19 is characterized by a highly dynamic
disease process, admission characteristics may only
incompletely capture the association of clinical risk
factors with AKI. We therefore present here a longitu-
dinal analysis of laboratory and clinical parameters in
relation to AKI development in 223 consecutive COVID-
19 patients hospitalized in one of Europe’s largest ter-
tiary care centers during the first wave of COVID-19.METHODS
Study Design
This retrospective observational cohort study was
approved by the local ethics committee (EA4/013/20).
We identified adult patients (n ¼ 236) with
906symptomatic COVID-19 disease who were admitted to
any of the 3 hospitals of the Charité–Uni-
versitätsmedizin Berlin between 1 March 2020 and 3
June 2020. Outcome data for death, discharge status,
and ICU and hospital lengths of stay were collected up
to 18 August 2020.
Inclusion and Exclusion Criteria
Patients had to be at least 18 years old, show signs or
symptoms consistent with COVID-19, and required a
positive reverse-transcriptase polymerase chain reac-
tion test result from an oropharyngeal swap, sputum,
or bronchioalveolar lavage fluid. Patients admitted for
other diagnoses who tested positive for SARS-CoV2 in
the screening swab upon hospital admission were not
included if no COVID-19–related symptoms occurred
during their hospital stay. We excluded patients with
preexisting dialysis-dependent chronic kidney disease
(CKD), patients in whom KRT for AKI was initiated in
another hospital before transfer to Charité, and patients
in whom medical therapy was palliatively limited on
the day of admission.
Data Collection and Data Preparation
Data on the disease course, patient demographics,
preexisting conditions and medications, laboratory and
clinical parameters, and outcomes were extracted from
electronic health records. Data cleaning and data
handling was done using Excel (Microsoft, Redmond,
WA) and Python 3 (Python Software Foundation,
Wilmington, DE) using the Pandas library. All pa-
rameters were assessed regarding plausibility by 2 in-
dependent clinicians. Values for parameters with upper
quantification limits (procalcitonin, D-dimer, inter-
leukin 6) were approximated with upper limit þ 1 unit.
The limits were as follows: procalcitonin, 100 mg/l; D-
dimer, 20 mg/l; and interleukin 6, 50 ng/ml. Very few
data points were above these limits. In 3 patients in the
severe AKI group, procalcitonin and interleukin 6
levels were above the upper limit. D-dimer values
above the upper detection limit were found in 10 pa-
tients in the AKI stage 3 group and in 2 patients in the
group not at AKI stage 3.
AKI Adjudication
AKI was defined and staged using the Kidney Disease:
Improving Global Outcomes (KDIGO) AKI criteria:
 Stage 1: Increase in serum creatinine by 0.3 mg/dl
within 48 hours or a 1.5- to 1.9-fold increase in serum
creatinine from baseline within 7 days or urine
output < 0.5 ml/kg/h for 6 to 12 hours
 Stage 2: 2.0- to 2.9-fold increase in serum creatinine
from baseline within 7 days or urine output of < 0.5
ml/kg/h for more than 12 hoursKidney International Reports (2021) 6, 905–915
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within 7 days, or an increase in serum creatinine >4
mg/dl, or initiation of KRT or urine output of <0.3
ml/kg/h for >24 hours or anuria for >12 hours.30
Urine output data were only available for all patients
admitted to the ICU.
Two clinicians independently adjudicated the
creatinine baseline values and the AKI diagnosis and
stage. The following guiding principles were applied in
the adjudication process. When preadmission creati-
nine values were available, the lowest of these values
was chosen. When no preadmission creatinine values
were available, but the admission creatinine value
corresponded to an estimated GFR (eGFR; CKD-
Epidemiology Collaboration) $ 75 ml/min per 1.73
m2, this value was chosen. When no preadmission
creatinine values were available and the admission
creatinine value corresponded to an eGFR (CKD-
Epidemiology Collaboration) < 75 ml/min per 1.73 m2,
the lowest stable creatinine level after recovery of the
index AKI was chosen. If none of these conditions
applied, the baseline creatinine value was reported as
missing (this applied to 11 patients). In patients for
whom the adjudicated baseline creatinine differed
by # 0.2 mg/dl between the 2 adjudicating clinicians,
the mean of the 2 values was used. When values
differed by > 0.2 mg/dl, the baseline creatinine values
were defined after a joint discussion.
The urine output data were extracted in the form of
time-series data from the ICU information system
(COPRA System GmbH, Berlin, Germany). The data
were preanalyzed by calculating moving averages of
the urine volumes divided by the respective body-
weight over 6-, 12-, and 24-hour windows and were
checked for the AKI criteria. The detected AKIs were
validated through a manual medical record review.
Outcomes
Severe AKI (stage 3 AKI according to KDIGO criteria)
was defined as the primary outcome, and the combi-
nation of stage 2 or stage 3 as the secondary outcome.30
Follow-up time was censored on 3 June 2020 for the
primary and secondary outcomes. Death and discharge
status were followed-up until 18 August 2020.
Definitions of Preexisting Conditions
Preexisting conditions, with the exception of CKD,
were recorded as documented by the treating physi-
cians in the electronic medical record. The presence of
significant CKD was defined as a baseline eGFR of < 60
ml/min per 1.73 m2, estimated from the adjudicated
baseline creatinine with the CKD-Epidemiology
Collaboration formula, assuming that the reduced
GFR had persisted for at least 3 months.31Kidney International Reports (2021) 6, 905–915Statistical Analysis
Absolute and relative frequencies are reported for
categorical variables, median along with interquartile
ranges (IQR) for ordinal and continuous variables for all
patients, and by primary outcome. Parameters
measured longitudinally before the event are summa-
rized with their minima or maxima and median per
patient.
Time-to-event analyses were based on a time-to-first-
event approach for the primary and the secondary
outcome. Competing-risk analysis was applied to
consider that the outcome and death without prior
occurrence of the outcome were competing risks. Cu-
mulative incidence curves were used to graphically
assess time to AKI stage 3 or death without AKI stage 3.
Cause-specific hazard ratios (HRs) of potential risk
factors were estimated based on multivariable Cox
proportional hazards regression models with time-
varying covariates. Parameters included into the
model were selected based on their representation of
potential AKI mechanisms and pathophysiological cat-
egories and based on their availability and complete-
ness in longitudinal clinical data (for details refer to
Supplementary Tables S1 and S2). In addition, the as-
sociation of all parameters with the outcome was
assessed in simplified models, only controlling for
baseline characteristics of sex, age, body mass index
(BMI), diabetes, hypertension, and baseline eGFR.
Incomplete data in baseline parameters and longi-
tudinal clinical parameters were addressed by multiple
imputation. The imputation model included baseline
characteristics (sex, age, BMI, diabetes, hypertension,
and baseline eGFR), longitudinal clinical parameters
(bilirubin, aspartate amino transferase, alanine amino
transferase, creatine kinase, myoglobin, hemoglobin,
platelet counts, leukocyte counts, neutrophil counts,
lymphocyte counts, C-reactive protein, serum pro-
calcitonin, interleukin 6, ferritin, D-dimer, lactate de-
hydrogenase, intensive care admission, vasopressor
use, mechanical ventilation, and extracorporeal mem-
brane oxygenation), whether the patient was trans-
ferred from another hospital, time since hospital
admission, and outcome (separately for the primary
AKI stage 3 outcome or the secondary AKI stage 2 and 3
outcome). The imputation was based on a classification
and regression tree algorithm with 100 imputed data
sets and a maximum of 5 iterations, taking into account
the clustered structure of the data set with multiple
measurements per patient. As a sensitivity analysis, the
described simplified competing-risk models were also
assessed without imputation in a complete-case
analysis.
Statistical analyses were performed using R software
(R Foundation for Statistical Computing, Vienna,907
Table 1. Baseline characteristics of the study cohort
Variable
Total No severe AKI Severe AKI
(N [ 223) (n [ 153) (n [ 70)
Demographics
Age, y 62.0 (51.0–75.0) 61.0 (47.0–75.0) 64.5 (56.0–74.8)
Male sex 147 (65.9) 95 (62.1) 52 (74.3)
Body mass
index, kg/m2
27.4 (24.0–31.7) 26.0 (22.9–29.7) 30.8 (26.3–34.6)
Missing 40 (17.9) 35 (22.9) 5 (7.1)
BMI > 30 kg/m2 62 (27.8) 29 (19.0) 33 (47.1)
Missing 40 (17.9) 35 (22.9) 5 (7.1)
Weight, kg 83.0 (75.0–96.7) 80.0 (70.0–88.4) 90.0 (80.0–110.0)
Missing 32 (14.3) 31 (20.3) 1 (1.4)
Comorbidities
Comorbidities, No. 1.0 (0.0–3.0) 1.0 (0.0–3.0) 2.0 (1.0–3.0)
Hypertension 120 (53.8) 70 (45.8) 50 (71.4)
Diabetes 52 (23.3) 30 (19.6) 22 (31.4)
Chronic kidney
disease $ G3
30 (13.5) 18 (11.8) 12 (17.1)
Baseline
Creatinine, mg/dl 0.9 (0.7–1.0) 0.8 (0.7–1.0) 1.0 (0.8–1.1)
eGFR ml/min
per 1.73m2
86.9 (70.7–100.5) 90.6 (74.3–103.1) 76.7 (62.8–93.1)
Missing 11 (4.9) 1 (0.7) 10 (14.3)
Creatinine on
admission, mg/dl
1.0 (0.8–1.4) 0.9 (0.8–1.2) 1.4 (1.0–2.2)
Coronary artery
disease
41 (18.4) 30 (19.6) 11 (15.7)
Myocardial infarction 33 (14.8) 23 (15.0) 10 (14.3)
Heart failure 19 (8.5) 16 (10.5) 3 (4.3)
Atrial fibrillation 29 (13.0) 21 (13.7) 8 (11.4)
Stroke/TIA 20 (9.0) 14 (9.2) 6 (8.6)
Peripheral vascular
disease
8 (3.6) 4 (2.6) 4 (5.7)
COPD 17 (7.6) 7 (4.6) 10 (14.3)
Asthma 14 (6.3) 9 (5.9) 5 (7.1)
Obstructive sleep
apnea
11 (4.9) 5 (3.3) 6 (8.6)
History of smoking 43 (19.3) 31 (20.3) 12 (17.1)
Active malignancy 8 (3.6) 6 (3.9) 2 (2.9)
Permanent medications
Medications, No. 1.0 (0.0–3.0) 1.0 (0.0–3.0) 1.0 (0.0–3.5)
Missing 5 (2.2) 2 (1.3) 3 (4.3)
ACE-I 41 (18.4) 25 (16.3) 16 (22.9)
ARB 42 (18.8) 30 (19.6) 12 (17.1)
b-Blocker 55 (24.7) 36 (23.5) 16 (22.9)
Diuretics 46 (20.6) 30 (19.6) 16 (22.9)
Inhalers for asthma
or COPD
16 (7.2) 9 (5.9) 7 (10.0)
Calcium channel
blockers
29 (13.0) 18 (11.8) 11 (15.7)
Antidiabetics 41 (18.4) 22 (14.4) 19 (27.1)
Antiplatlets 39 (17.5) 24 (15.7) 15 (21.4)
Anticoagulants 31 (13.9) 25 (16.3) 6 (8.6)
Immunosuppressants 16 (7.2) 13 (8.5) 3 (4.3)
Statins 50 (22.4) 36 (23.5) 14 (20.0)
ACE-I, angiotensin-converting enzyme inhibitor; AKI; acute kidney injury, ARB; angio-
tensin II receptor blocker; COPD, chronic obstructive pulmonary disease; eGFR, esti-
mated glomerular filtration rate; TIA, transient ischemic attack.
Data are displayed as median (interquartile range) or n (%).
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During the first wave of COVID-19 in Germany, from 1
March 2020 to 3 June 2020, 236 patients were admitted
to 1 of 3 sites of the Charité–Universitätsmedizin Berlin
for symptomatic COVID-19 disease, 223 of whom were
included in this analysis. Reasons for exclusion are
provided in the study diagram (Supplementary
Figure S1). A high proportion of patients, 86 of 223
(38.6%), were referred from other hospitals, because
the hospitals included in this study were designated as
tertiary referral centers for particularly severe cases
(Supplementary Table S3). There were 57 patients
(25.6%) referred from external ICUs (secondary ICU
transfers). Before arrival at Charité hospitals, 58 pa-
tients (26%) had been intubated as part of their
emergency care or within external ICUs. Table 1 sum-
marizes baseline characteristics of the study cohort.
Patients were a median age of 62 years (IQR, 51–75
years), 65.9% were men, and the median BMI was 27.4
kg/m2 (IQR, 24.1–31.5 kg/m2). The most common
comorbidities were hypertension (53.3%), diabetes
(23.3%), and coronary artery disease (18.4%). CKD
stage G3–5 was present in 13.5% of patients. The me-
dian baseline eGFR was 86.9 ml/min per 1.73 m2 (IQR,
70.7–100.5 ml/min per 1.73 m2).
Incidence and Severity of AKI
Any stage of AKI developed in 117 patients (52.4%)
(Supplementary Table S4). The maximum AKI severity
was stage 1 in 24 patients, stage 2 in 23 patients, and
stage 3 in 70 patients (Supplementary Table S4). AKI
stage 1 patients were frequently treated in the non-ICU
setting, but treatment for AKI stages 2 and 3 patients
occurred almost exclusively in the ICU (Supplementary
Table S4). For the purposes of this study, AKI stage 3
(severe AKI) was defined as the primary analysis
outcome, because it is of established clinical importance
in that it is closely coupled to the need for KRT and has
the worst outcomes among AKI stages.
On the first day of a diagnosis of severe AKI, 18
patients (26%) showed creatinine criteria for AKI stage
3 (3-fold increase of creatinine or increase of creatinine
to a value of > 4 mg/dl), 48 patients (69%) showed
urinary output criteria of AKI stage 3 (<0.3 ml/kg/h for
>24 hours or anuria for >12 hours), and 52 patients
fulfilled the KRT criterion of AKI stage 3. The AKI stage
3 diagnosis was driven by KRT alone in 20 patients
(29%) (Supplementary Table S5). All severe AKI cases
developed throughout the first 20 days of908hospitalization, with a wide range of time spans to
severe AKI development (Supplementary Figure S2).
Patients with severe AKI were older, more frequentlyKidney International Reports (2021) 6, 905–915
Table 2. Time-varying parameters in COVID-19 patients with and
without severe AKI
Variable
No severe AKI Severe AKI
(n [ 153) (n [ 70)
Mechanical ventilation
No. (%) 29 (19.0) 67 (95.7)
Need for vasopressorsa
No. (%) 29 (19.0) 66 (94.3)
Hemoglobin, g/dl
Median 12.3 (10.2–13.5) 10.6 (9.5–12.4)
Min 11.6 (9.1–12.7) 9.9 (8.7–11.7)
n 153 70
Thrombocyte count, count/nl
Median 258.5 (202.0–333.0) 238.6 (159.8–327.9)
Min 187.0 (149.0–234.0) 194.0 (134.8–264.8)
n 153 70
Leucocyte count, count/nl
Median 6.6 (5.3–7.6) 10.6 (7.4–14.3)
Max 8.2 (6.3–11.5) 14.3 (9.9–17.7)
n 152 70
Neutrophil count, count/nl
Median 4.5 (3.3–5.8) 8.2 (5.6–10.4)
Max 6.1 (4.2–8.9) 10.2 (7.3–12.8)
n 151 52
Lymphocyte count, count/nl
Median 1.2 (0.9–1.5) 0.9 (0.6–1.1)
Min 0.9 (0.7–1.1) 0.7 (0.5–1.0)
n 151 52
Neutrophil/lymphocyte ratio
Median 6.6 (5.3–7.6) 10.6 (7.4–14.3)
Max 8.2 (6.3–11.5) 14.3 (9.9–17.7)
n 152 70
Total bilirubin, mg/dl
Median 0.4 (0.3–0.6) 0.6 (0.4–1.0)
Max 0.6 (0.4–0.8) 0.8 (0.6–1.5)
n 149 70
AST, U/l
Median 44.0 (30.0–59.0) 69.0 (56.4–113.5)
Max 59.0 (37.0–103.0) 90.0 (65.8–134.2)
n 125 62
ALT, U/l
Median 38.0 (24.5–74.2) 40.1 (28.5–55.2)
Max 63.0 (31.5–105.0) 49.5 (32.2–72.8)
n 127 62
Creatine kinase, U/l
Median 65.5 (40.4–97.8) 326.8 (164.2–1064.8)
Max 110.0 (64.2–288.2) 629.5 (262.2–1945.5)
n 144 68
Myoglobin, mg/l
Median 46.0 (32.0–92.5) 429.0 (140.0–1520.0)
Max 71.0 (38.0–216.5) 799.0 (174.0–2358.0)
n 37 47
LDH, U/l
Median 311.5 (274.5–370.0) 487.0 (409.0–602.0)
Max 397.0 (329.0–507.5) 570.0 (486.0–697.0)
n 151 69
D-dimer,b mg/l
Median 1.6 (0.9–2.9) 3.3 (1.4–8.4)
Max 2.7 (1.1–6.1) 4.2 (1.5–12.2)
n 69 59
(Continued on following page)
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preexisting CKD, and chronic obstructive pulmonary
disease were more frequent in patients with severe AKI
(Table 1). KRT was initiated in 67 of 70 patients
(95.7%) during the course of severe AKI. Continuous
KRT was used in the initial phase, and intermittent
hemodialysis was also used later during the course of
the disease.
Disease Course, Time-Varying Clinical Parame-
ters, and Their Association With AKI
Overall, 138 patients (61.9%) were admitted to an
ICU at or during the course of hospitalization. Of
these, 96 (69.6%) were mechanically ventilated, and
32 (23.2%) received extracorporeal membrane
oxygenation. Severe AKI developed predominantly in
patients who were mechanically ventilated (68 of 70
of severe AKI cases [97.1%]) and who received
vasopressor support (66 of 70 of severe AKI cases
[94.3%]). In mechanically ventilated patients, AKI
occurred mostly after intubation (67 of 68 patients),
with a median time lag of 4 days (IQR, 1–9 days)
(Supplementary Figure S3).
We collected time-varying clinical parameters
throughout the disease course and examined their as-
sociation with severe AKI development. These param-
eters included laboratory tests and treatment
parameters, including the need for mechanical venti-
lation and for vasopressor therapy (for selected key
parameters see Table 2; for a full list of parameters see
Supplementary Table S1). Consistent with the obser-
vation that severe AKI was confined to patients treated
in ICUs, mechanical ventilation and vasopressors were
more frequently used in these patients. Similarly, de-
viations of laboratory parameters from normal values
were usually more pronounced in patients with severe
AKI (Table 2).
To identify risk factors for COVID-19–associated
severe AKI, we analyzed baseline parameters (static
covariates) together with longitudinal parameters
(time-varying covariates) in an explanatory multivari-
able risk model with severe AKI as the main outcome.
Death without prior severe AKI, which occurred pri-
marily during the later disease course (Supplementary
Figure S2), was considered as a competing risk. We
constructed a main model using 6 baseline and 11 time-
dependent parameters and a reduced model with 5
baseline and 8 time-dependent parameters (Figure 1).
The approach was hypothesis driven, in that parame-
ters selected for analysis were chosen based on their
putative contribution to the pathophysiology of AKI
and on their availability across the entire cohort
(Supplementary Tables S1 and S2). The main fullyKidney International Reports (2021) 6, 905–915 909
Table 2. (Continued)
Variable
No severe AKI Severe AKI
(n [ 153) (n [ 70)
CRP, mg/dl
Median 51.0 (18.6–82.4) 229.9 (135.5–334.6)
Max 100.8 (42.5–182.6) 330.3 (188.9–419.0)
n 153 70
Procalcitonin,b mg/l
Median 0.1 (0.0–0.1) 1.1 (0.5–2.7)
Max 0.1 (0.1–0.5) 2.1 (0.8–5.0)
n 148 69
Interleukin-6,b ng/l
Median 18.8 (6.5–37.7) 262.3 (102.2–679.5)
Max 48.5 (15.9–108.1) 507.8 (216.8–1402.8)
n 138 50
Ferritin, mg/l
Median 654.4 (399.6–1149.7) 1530.8 (879.6–2591.8)
Max 871.5 (453.1–1526.6) 1910.3 (980.8–2909.9)
n 141 56
AKI, acute kidney injury; ALT, alanine Aminotransferase; AST, aspartate aminotrans-
ferase; CRP; C-reactive protein; LDH, lactate dehydrogenase.
aIncludes norepinephrine and vasopressin.
bWhen data points exceeded the upper detection limit. these values were imputed as
upper limit þ 1 unit.
Displayed are medians (interquartile range) of individual patient’s median and individual
patient’s extreme values (maximum or minimum, as appropriate) during the in-hospital
disease course, and n indicates the group size. For parameters in the AKI stage 3 group,
only data preceding AKI stage 3 were considered.
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revealed that the need for mechanical ventilation or
vasopressors, blood leucocyte counts, and serum pro-
calcitonin levels were significant time-dependent risk
factors of severe AKI.
Separate analyses of longitudinal parameters were
conducted in simplified, minimally adjusted models
(adjustment for sex, age, hypertension, diabetes, eGFR,
and BMI) (Supplementary Figure S4) and confirmed
these risk factors. To confirm that these results were
specific to AKI, we conducted a sensitivity analysis,
repeating the risk modeling with a combined AKI stage
2/3 outcome, which was defined by the earliest
occurrence of AKI stage 2 or stage 3. This analysis
yielded a virtually identical model (Supplementary
Figure S5).
We next visualized the time courses of the inde-
pendent risk factors in relation to the development of
severe AKI (Figure 2, Supplementary Figures S6–S8).
This confirmed that mechanical ventilation
(Supplementary Figure S6) and the need for vaso-
pressor therapy (Supplementary Figure S7) frequently
preceded the onset of severe AKI. In addition, heat map
visualizations indicated that there was a particularly
close temporal association between increasing serum
procalcitonin levels and the onset of severe AKI
(Supplementary Figure S2). A similarly close temporal
association was observed for increasing blood leucocyte
counts and severe AKI (Supplementary Figure S8).910Outcomes of Patients With Severe AKI
Among patients with severe AKI, 47.1% died during
the hospital stay, 45.7% were discharged, and 7.1%
continued to be hospitalized (Table 3). In contrast,
among patients without severe AKI, only 6.5% died,
and the remaining 93.5% were discharged.DISCUSSION
This analysis of a heterogeneous cohort of COVID-19
patients consecutively hospitalized in 3 sites of a
large tertiary care center provides a longitudinal clin-
ical characterization of COVID-19 patients and its as-
sociation with AKI. Severe AKI was restricted to ICU
patients. Measures of COVID-19–associated critical
illness (the need for vasopressors and mechanical
ventilation) and increasing blood levels of markers of
systemic inflammation (serum procalcitonin and blood
leucocytes) emerged as key time-varying risk factors
for severe AKI. A particularly close temporal associa-
tion was observed for increasing markers of systemic
inflammation with the onset of severe AKI. Procalci-
tonin and blood leucocytes have both been previously
described as predictive of adverse disease courses and
mortality in COVID-19 and indicate an exaggerated
inflammatory response.37 D-dimer and lactate dehy-
drogenase, additional established risk factors of severe
COVID-19 courses,38–40 were not independently asso-
ciated with severe AKI, although they were predictive
in simplified models. A noteworthy finding is that we
did not observe severe AKI outside the ICU setting,
confirming the close association of AKI with the overall
COVID-19 disease severity and arguing against an iso-
lated development of severe AKI in COVID-19 patients
who are not critically ill. Our data are consistent with
Hirsch et al.,4 who identified mechanical ventilation
and vasopressor use as important AKI determinants in
COVID-19. However, their analysis was confined to
admission data and did not consider time-varying
clinical parameters.
The frequencies of AKI (52.4%) and of KRT (30%) in
our cohort are markedly higher than in a recently
published German nationwide observational study of
10,021 hospitalized patients based on administrative
records and in cohorts from New York during the surge
of COVID-19.4,6,7 A likely explanation for this is that
our study was conducted in a tertiary care center with
a large proportion of secondary referrals of critically ill
patients. Our cohort consistently displayed high rates
of ICU admission (62.2%) and mechanical ventilation
(43.5%). This rate of mechanical ventilation was also
markedly higher than the reported nationwide me-
chanical ventilation rate of 17% for COVID-19 patients
in Germany.7Kidney International Reports (2021) 6, 905–915
Figure 1. Longitudinal risk factors of severe acute kidney injury (AKI) during the COVID-19 disease course. Multivariable Cox proportional
hazards regression with time-varying covariates was used to estimate hazards of potential risk factors for time to severe AKI, along with 95%
confidence intervals (CI). Estimates were derived from 2 multivariable competing-risk models with time-varying covariates, adjusted for all
parameters displayed. Missing data were addressed by multiple imputation. A main multivariable model (including 11 time-varying risk factor
covariates) and a reduced model (including 8 time-varying risk factor covariates) were fitted to account for partially overlapping clinical in-
formation content of the time-dependent risk factors of severe AKI. Dots indicate hazard ratio estimates, and the horizontal bars indicate 95%
CIs. *When data points exceeded the upper detection limit these values were imputed as upper limit þ 1 unit. BMI, body mass index; CRP, C-
reactive protein; eGFR, estimated glomerular filtration rate; LDH, lactate dehydrogenase.
J-HB Hardenberg et al.: Severe AKI in COVID-19 CLINICAL RESEARCHIt is important to note that health care resources in
Germany, including those in the catchment area of this
study, were not overwhelmed during the first wave
of the pandemic, with sufficient ICU capacity to
manage severely ill patients. Nevertheless, normal
ward capacities were reduced during the surge of the
pandemic, and mild and moderate courses of COVID-19
were treated outside the hospital setting. This would be
consistent with our observation that most of the cases
of AKI in our cohort were KDIGO stage 3, in sharp
contrast to a previous retrospective analysis of AKI
cases in the same health care setting before the onset of
the pandemic, where less severe AKI stages were sub-
stantially more frequent compared with stage 3.41
Although mechanical ventilation and vasopressor
use emerged as risk factors of severe AKI, the start of
mechanical ventilation or initiation of vasopressors
frequently preceded severe AKI development by
several days. In contrast, increasing serum procalcito-
nin levels and blood leucocyte counts frequently
coincided with start of AKI. One might speculate, on
the basis of these data, that respiratory and circulatory
failure in COVID-19 may create a permissive situation
during which kidney function may initially be pre-
served before an exaggerated systemic inflammation
precipitates organ failure.Kidney International Reports (2021) 6, 905–915An obvious candidate scenario causing decompen-
sation may be a superimposed bacterial infection.
Bacterial infections are common in other viral pneu-
monias, particularly influenza, and serum procalcitonin
levels associate with bacterial infections, particularly
bacterial pneumonia.42 Nevertheless, recent studies
have highlighted a lack of specificity of procalcitonin
for bacterial infections,43 and elevated procalcitonin
release has been observed in various disease processes,
including liver failure, cardiogenic shock, major burns,
or major surgery.44–47 In fact, SARS-CoV2 itself may
directly cause systemic immune activation and thereby
precipitate a hyperinflammatory clinical picture, with
high procalcitonin and white blood cell elevation. The
reasons for the sometimes abrupt increases in these
markers in patients who had already been treated in
ICUs for several days are currently unknown. Experi-
mental evidence suggests that kidney injury may not
only be the consequence of respiratory failure, but also
conversely aggravate lung injury.10 It is therefore
possible that interorgan cross talk might contribute to
the observed temporal associations.
Our findings imply that AKI is strongly linked to the
overall COVID-19 disease course rather than being an
independent complication. Whether direct viral infec-
tion of the kidney occurs in patients with COVID-19 is911
Figure 2. Heat map visualization of serum procalcitonin levels over time and their relationship to severe AKI (AKI stage 3) in all 223 patients
included in the study. Displayed are procalcitonin levels in ng/l over time (grey cells indicating missing data). Days with AKI stage 3 are labeled
by black boxes. Every row represents 1 patient and each column 1 day of hospitalization. Day 0 refers to the day of admission to Charité
university hospitals. Patients are sorted on the basis of whether they were ever admitted to an intensive care unit (ICU). Patients ever admitted
to the ICU were then sorted by AKI stage 3 status and by the start and duration of AKI stage 3.
Table 3. Outcomes of the study cohort split by severe AKI status
General outoome
Total No severe AKI Severe AKI
(N [ 223) (n [ 153) (n [ 70)
Death during hospitalization 43 (19.3) 10 (6.5%) 33 (47.1%)
Ongoing hospitalization 5 (2.2) 0 (0%) 5 (7.1%)
Ongoing ICU stay 4 (1.8) 0 (0) 4 (5.7)
Discharge acute care 175 (78.5) 143 (93.5) 32 (45.7)
Total hospital stay, d 17.5 (9.0–34.0) 14 (8.0–23.0) 40 (22.25–60.75)
Total ICU stay, d 20.5 (7.0–43.0) 9 (5.0–20.0) 34 (21.0–56.0)
AKI, acute kidney injury; ICU, intensive care unit.
Data are presented as n (%) or median (interquartile range).
CLINICAL RESEARCH J-HB Hardenberg et al.: Severe AKI in COVID-19a matter of current debate.15,16,18,19,48 If it does occur
during the early phases of the disease, it does not seem
to be sufficient on its own to cause severe AKI. Our
findings are consistent with recent histopathologic
studies of kidney tissue from autopsies of COVID-19
patients showing predominantly acute tubular necro-
sis, as in patients with AKI and critical illness of other
etiology.18,19
Our study has strengths and limitations. We were
fortunate that our health care system was not over-
whelmed, allowing us to assess the disease course inde-
pendently of the impact of resource limitations, such as
very late referrals or triaging. Further strengths include
the availability of high-quality time-resolved clinical data.
We achieved comprehensive identification of
different stages of AKI based on clinical adjudication,
which included urinary output data and high-
resolution creatinine dynamics. The availability of912baseline creatinine data was high (95.1%), contrasting
markedly with <20% complete data in previous
studies.4
The size of this cohort (223 patients) is relatively
small, and analyses were restricted to routine clinical
data. Nevertheless, the high incidence rate of AKI in thisKidney International Reports (2021) 6, 905–915
CODE AVAILABILITY
The code (written in R) used for the statistical modeling will be
made available upon request.
J-HB Hardenberg et al.: Severe AKI in COVID-19 CLINICAL RESEARCHpopulation added substantial power to the statistical
modeling approaches. Because the hospitals involved in
this study were the highest level referral centers for
COVID-19 patients, our cohort includes several severely
ill patients referred from external ICUs. Therefore,
general conclusions regarding the frequency of critical
illness, AKI, and KRT in COVID-19 patients cannot be
derived from our cohort. In addition, data available from
external ICUs were limited to the date of symptom onset
and the dates of initiation of mechanical ventilation or
KRT. We therefore cannot exclude that a subset of pa-
tients experienced non–KRT-dependent AKI at external
hospitals before admission at Charité.
In addition, urinary output data were restricted to
ICU patients, which may potentially bias AKI stage 3
adjudication to the ICU setting.
Owing to the retrospective study design, longitu-
dinal clinical data had variable levels of completeness,
but analysis with and without multiple imputation
approaches indicated that the predictors of severe AKI
remained consistent. Previous studies have highlighted
that high serum interleukin 6, interleukin 8, and tumor
necrosis factor-a levels and high neutrophil/lympho-
cyte ratios were strong and independent predictors of
disease severity and patient survival in COVID-19.49–52
However, the limited longitudinal availability or
absence of these parameters in routine clinical data
prevented us from assessing the impact of these pa-
rameters on severe AKI development.CONCLUSION
Severe forms of AKI in COVID-19 are confined to crit-
ically ill patients and intricately linked to overall dis-
ease severity. Markers of critical illness and systemic
inflammation were key time-varying risk factors of
severe AKI development. In contrast, severe AKI did
not occur uncoupled from overall COVID-19 severity.DISCLOSURE
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